Posted by
Psychiatric Associates of Southwest Florida (PASWFL) Uses the FDA Recommended Risk Evaluation and Mitigation Strategy (REMS) for All Our Ketamine Treatments

Psychiatric Associates of Southwest Florida (PASWFL) Uses the FDA Recommended Risk Evaluation and Mitigation Strategy (REMS) for All Our Ketamine Treatments

Robert Pollack MD – CEO and head psychiatrist at PASWFL, is a certified Risk Evaluation Mitigation Strategy provider. The REMS program that Dr. Pollack is certified in was approved by the US Food and Drug Administration (FDA). You can read more about the particular parameters that must be met for the safe administration of esketamine […]

Posted by
Ketamine and Future Depression Treatments

Ketamine and Future Depression Treatments

Researchers are hailing ketamine as the most significant new development in psychiatry given its high efficacy for treating major depression. Recent evidence has shown that in addition to depression, ketamine may also be a promising treatment for obsessive-compulsive disorder, post-traumatic stress disorder, and a number of other treatment-refractory neuropsychiatric disorders. In a recent paper published in Drug Discovery […]

Posted by
Ketamine as a Treatment for Postpartum Depression

Ketamine as a Treatment for Postpartum Depression

Abstract Postpartum depression (PPD) affects over 10% of new mothers and adversely impacts the health of offspring. One of the greatest risk factors for PPD is prepregnancy stress but the underlying biological mechanism is unknown. Here we constructed an animal model which recapitulated prepregnancy stress induced PPD and tested the role of Akt-mTOR signaling in […]

Posted by
Ketamine Found Effective for Patients With Anxious Treatment-Resistant Depression

Ketamine Found Effective for Patients With Anxious Treatment-Resistant Depression

Patients with anxious depression—major depressive disorder (MDD) with high levels of anxiety—are known to have a poorer response to commonly used antidepressants than those with MDD. A small study published in Depression & Anxiety now suggests intravenous (IV) ketamine may be able to reduce symptoms in patients with anxious depression. The study found patients with and without anxious depression […]

Posted by
Is the Ketamine Boom Getting out of Hand? A Response.

Is the Ketamine Boom Getting out of Hand? A Response.

On September 26 2018 Scientific American published an article calling out some of the business practices being used by ketamine treatment providers across the country. The article summarized legitimate concerns about the business side of the ketamine while reiterating the promise ketamine shows as a breakthrough treatment for difficult to treat cases of depression. “This […]

Posted by
A Deeper Understanding of Major Depressive Disorder is Within Reach

A Deeper Understanding of Major Depressive Disorder is Within Reach

WHY AREN’T SOME PATIENTS WITH MDD REACHING REMISSION? For more than 50 years, major depressive disorder (MDD) pharmacological treatment approaches have focused on increasing the level of monoamine neurotransmitters in the brain, with the hope of reducing symptoms.1 And while conventional antidepressants have helped most, the STAR*D trial* found that one-third of patients didn’t achieve remission after multiple treatment […]

Posted by

The Glutamate Hypothesis in Synaptic Connectivity

Glutamate neurotransmission is an active area of research in major depressive disorder (MDD).1 Much of this interest revolves around glutamate’s role in regulating synaptic connectivity, one of several pathways that may strengthen and initiate the formation of new synaptic connections.1 As research advances, a deeper understanding of MDD is within reach. Watch our video featuring Dr […]